

Please type a plus sign (+) inside this box

+

PTO/SB/05 (2/98)

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

Attorney Docket No.

240083.501D6

First Inventor or Application Identifier

Mary E. Brunkow et al.

Title

IDENTIFICATION OF THE GENE CAUSING THE MOUSE
SCURFY PHENOTYPE AND ITS HUMAN ORTHOLOG

Express Mail Label No.

EL615486917US

Only for nonprovisional applications under 37 CFR § 1.53(b)

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 202311. ☒ General Authorization Form & Fee Transmittal
(Submit an original and a duplicate for fee processing)2. ☒ Copy of Specification [Total Pages] **47**
(preferred arrangement set forth below)

- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. ☒ Copy of Drawing(s) (35 USC 113) [Total Sheets] **10**4. Oath or Declaration [Total Pages] **2**a. ☐ Newly executed (original or copy)b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)

- i.
- ☐
- DELETION OF INVENTOR(S)**
-
- Signed statement attached deleting
-
- inventor(s) named in the prior
-
- application,
-
- see 37 CFR 1.63(d)(2) and 1.33(b)

5. ☒ Incorporation By Reference (useable if box 4b is checked) The
entire disclosure of the prior application, from which a copy of the
oath or declaration is supplied under Box 4b, is considered to be
part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.6. ☐ Microfiche Computer Program (Appendix)7. Nucleotide and Amino Acid Sequence Submission
(if applicable, all necessary)

- a.
- ☐
- Computer-Readable Copy
-
- b.
- ☐
- Paper Copy (identical to computer copy)
-
- c.
- ☐
- Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS8. ☐ Assignment Papers (cover sheet & document(s))9. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee) ☒ Copy of Power of
Attorney10. ☐ English Translation Document (if applicable)11. ☒ Information Disclosure
Statement (IDS)/PTO-1449 ☐ Copies of IDS
Citations12. ☒ Preliminary Amendment13. ☒ Return Receipt Postcard14. ☐ Small Entity
Statement(s) ☐ Statement filed in prior application,
Status still proper and desired15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)16. ☒ Other: Certificate of Express Mail
Check No. 13639 for \$ 1,268.00
Copy of Associate Power of Attorney17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information below and in a preliminary amendment☐ Continuation ☒ Divisional ☐ Continuation-In-Part (CIP)of prior Application No.: 09/372,668 filed 08/11/99Prior application information: Examiner Sumesh Kaushal Ph.D.Group / Art Unit 1633☒ Claims the benefit of Provisional Application No. 60/096,195 filed August 11, 1998**CORRESPONDENCE ADDRESS**

00500

Gary M. Myles, Ph.D.
Seed Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900 Fax: (206) 682-6031

Respectfully submitted,

TYPED or PRINTED NAME Gary M. Myles, Ph.D.SIGNATURE Gary M. Myles

U:\GaryMclient folders\Chiroscience\501D6\Divisional Application

REGISTRATION NO. 46,209Date October 25, 2000

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mary E. Brunkow et al.
Title : IDENTIFICATION OF THE GENE CAUSING THE MOUSE SCURFY PHENOTYPE AND ITS HUMAN ORTHOLOG
Docket No. : 240083.501D6
Date : October 25, 2000

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

GENERAL AUTHORIZATION UNDER 37 C.F.R. § 1.136(a)(3)
AND FEE TRANSMITTAL

Assistant Commissioner for Patents:

With respect to the above-identified application, the Assistant Commissioner is authorized to treat any concurrent or future reply requiring a petition for an extension of time under 37 C.F.R. § 1.136(a)(3) for its timely submission as incorporating a petition therefor for the appropriate length of time. The Assistant Commissioner is also authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 19-1090.


With respect to the above-identified application, the fee is calculated below:

For	Number filed	Number extra		Rate		
Basic Fee						\$ 710
Total Claims	36	16	X	\$ 18	=	\$ 288
Independent Claims	1	0	X	\$	=	\$
Multiple Dependent Claim					+	\$ 270
Assignment Fee					+	\$
TOTAL FILING FEE						\$ 1,268
Extension-of-time fee (parent)					+	\$
TOTAL						\$ 1,268

A check in the amount of \$ 1,268.00 is enclosed to cover the filing fee.

The Assistant Commissioner is authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required, or credit any overpayment, to Deposit Account No. 19-1090. A duplicate copy of this request is enclosed.

Date October 25, 2000



Gary M. Myles, Ph.D.
Registration No. 46,209

GMM:cew

Seed Intellectual Property Law Group PLLC
701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

U:\GaryM\Client Folders\Celltech Chiroscience\240083\501D6\Divisional application\General Authorization Form and Fee Transmittal.doc

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Present Application:

Applicants : Mary E. Brunkow, Eric W. Jeffery, Kathryn A. Hjerrild
and Fred Ramsdell
Title : IDENTIFICATION OF THE GENE CAUSING THE MOUSE
SCURFY PHENOTYPE AND ITS HUMAN ORTHOLOG
Docket No. : 240083.501D6
Date : October 25, 2000

Prior Application:

Examiner : Sumesh Kaushal Ph.D.
Art Unit : 1633
Application No. : 09/372,668

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents:

Prior to examining the present application, Applicants respectfully request entry of the following amendments to the specification and claims.

In the Specification:

Please amend the specification as follows:

On page 1, please delete lines 4-7 and replace therefor:

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of pending United States Patent Application No. 09/372,668 filed August 11, 1999, which application claims priority from United States Provisional Patent Application No. 60/096,195 filed August 11, 1998, which applications are incorporated herein by reference in their entirety.--

In the Claims:

Please cancel claims 1-11 and 24-25.


REMARKS

With entry of this Preliminary Amendment, claim 34 is under consideration in the pending application. Claims 1-11 and 24-25 are cancelled and claims 12-23 and 26-33 are withdrawn from consideration pursuant to the Restriction Requirement mailed in U.S. Patent Application 09/372,668 on April 26, 2000. By this Amendment, the specification is amended to add the section entitled "CROSS-REFERENCE TO RELATED APPLICATIONS" which section recites Applicants' claim to priority. This amendment does not add new matter to the specification. Applicants respectfully request entry of this amendment.

Applicants submit that, with this amendment, each of the pending claims is in consideration for allowance and respectfully request that the Examiner issue a Notice to that effect. Should the Examiner have any additional questions, he is respectfully encouraged to contact the undersigned attorney at (206) 622-4900.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Gary M. Myles, Ph.D.

Registration No. 46,209

GMM:cew

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

U:\GaryM\Client Folders\Celltech Chiroscience\240083\501D6\Divisional Application\Preliminary Amendment as filed

IDENTIFICATION OF THE GENE CAUSING THE MOUSE SCURFY
PHENOTYPE AND ITS HUMAN ORTHOLOG

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims priority from U.S. Provisional Application No. 60/096,195, filed August 11, 1998, which application is incorporated by reference in its entirety.

TECHNICAL FIELD

10 The present invention relates generally to pharmaceutical products and methods and, more specifically, to methods and compositions useful for diagnosing scurfy-related diseases, as well as methods for identifying compounds which can modulate the immune system.

BACKGROUND OF THE INVENTION

15 Inherited mutations affecting the murine immune system have proven to be a rich source of novel genes critical to the regulation of the immune system and have furnished important animal models for human immunological disorders. These include *xid*, the murine equivalent of X-linked agammaglobulinemia (Thomas et al., *Science* 261:355, 1993; Rawlings et al., *Science* 261:358, 1993), beige (the equivalent of Chediak-Higashi Syndrome) (Barbosa, et al., *Nature* 382:262, 1996), *lpr* and *gld* 20 (defects in fas and fas-ligand), X-linked severe combined immunodeficiency (Sugamura et al., *Annu. Rev. Immunol.* 14:179, 1996), and the hematopoietic cell phosphatase mutant motheaten (SHP-1) (Bignon and Siminovitch, *Clin Immunol Immunopathol* 73:168, 1994).

25 One mouse mutant of particular interest is the as-yet uncloned X-linked mouse mutant, scurfy (*sf*). Briefly, mice hemizygous for the scurfy mutation exhibit a severe lymphoproliferative disorder. In particular, males hemizygous (X^{sf}/Y) for the scurfy mutation develop a progressive lymphocytic infiltration of the lymph nodes.

spleen, liver and skin resulting in gross morphological symptoms which include splenomegaly, hepatomegaly, greatly enlarged lymph nodes, runting, exfoliative dermatitis, and thickened malformed ears (Godfrey et al., *Amer. J. Pathol.* 138:1379, 1991; Godfrey et al., *Proc. Natl. Acad. Sci. USA* 88:5528, 1991). Other clinical

5 symptoms include elevated leukocyte counts, hypergammaglobulinemia, and severe anemia (Lyon et al., *Proc. Natl. Acad. Sci. USA* 87:2433, 1990); the death of affected males usually occurs by 3 weeks of age. The *sf* locus has been mapped to the extreme proximal region of the X chromosome, approximately 0.7 centimorgans from the locus for *sparse-fur* (*spf*) (Lyon et al., *Proc. Natl. Acad. Sci. USA* 87:2433, 1990; Blair et al.,

10 *Mamm. Genome* 5:652, 1994), itself a point mutation within the ornithine transcarbamylase gene (*Otc*) (Veres et al., *Science* 237:415, 1987). The *sf* locus is also tightly linked to the murine *Gata1*, *Tcf3*, and *Wasp* loci (Blair et al., *Mamm. Genome* 5:652, 1994; Derry et al., *Genomics* 29:471, 1995). Similarities between scurfy and human Wiskott-Aldrich syndrome (WAS) have been noted (Lyon et al., *Proc. Natl.*

15 *Acad. Sci. USA* 87:2433, 1990), and the mouse *Wasp* gene has been proposed as a candidate for *scurfy* (Lyon et al., *Proc. Natl. Acad. Sci. USA* 87:2433, 1990; Derry et al., *Genomics* 29:471, 1995). Closer biological examination reveals significant differences between WAS and scurfy, however, and the two loci have been demonstrated to be non-allelic (Jeffery & Brunkow, unpublished data). Thus, prior to

20 applicants' invention the identity of the scurfy gene remained to be determined.

The present invention discloses methods and compositions useful for diagnosing scurfy-related diseases, as well as methods for identifying compounds which can modulate the immune system, and further provides other related advantages.

SUMMARY OF THE INVENTION

25 The present invention relates generally to the discovery of novel genes which, when mutated, results in a profound lymphoproliferative disorder. In particular, a mutant mouse, designated 'Scurfy', was used to identify the gene responsible for this disorder through backcross analysis, physical mapping and large-scale DNA

009696967-10969696

sequencing. Analysis of the sequence of this gene indicated that it belongs to a family of related genes, all containing a winged-helix DNA binding domain.

Thus, within one aspect of the invention isolated nucleic acid molecules are provided which encode FKH^{sf} or Fkh^{sf}, including mutant forms thereof. Within
 5 certain embodiments, Fkh^{sf} of any type may be from a warm-blooded animal, such as a mouse or human. Within further embodiments, isolated nucleic acid molecules are provided wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule that encodes an amino acid sequence comprising SEQ ID Nos
 2, or, 4, (b) a nucleic acid molecule that hybridizes under stringent conditions to a
 10 nucleic acid molecule having the nucleotide sequence of SEQ ID Nos: 1, or, 3, or its complement, and (c) a nucleic acid molecule that encodes a functional fragment of the polypeptide encoded by either (a) or (b). Preferably, the nucleic acid molecule is not JM2. Within related aspects, vectors (including expression vectors), and recombinant host cells are also provided, as well as proteins which are encoded by the above-noted
 15 nucleic acid molecules. Further, fusion proteins are also provided which combine at least a portion of the above-described nucleic acid molecules with the coding region of another protein. Also provided are oligonucleotide fragments (including probes and primers) which are based upon the above sequence. Such fragments are at least 8, 10, 12, 15, 20, or 25 nucleotides in length, and may extend up to 100, 200, 500, 1000, 1500,
 20 or, 2000 nucleotides in length.

Within other aspects methods of using the above noted expression vector for producing a Fkh^{sf} protein (of any type) are provided, comprising the general steps of (a) culturing recombinant host cells that comprise the expression vector and that produce Fkh^{sf} protein, and (b) isolating protein from the cultured recombinant host cells.

25 Also provided are antibodies and antibody fragments that specifically bind to Fkh^{sf} proteins. Representative examples of such antibodies include both polyclonal and monoclonal antibodies (whether obtained from a murine hybridoma, or derived into human form). Representative examples of antibody fragments include F(ab')₂, F(ab)₂, Fab', Fab, Fv, sFv, and minimal recognition units or complementarity
 30 determining regions.

09696967-102500

Within yet other aspects, methods are provided for detecting the presence of a *Fkh^{sf}* nucleic acid sequence in a biological sample from a subject, comprising the steps of (a) contacting a *Fkh^{sf}* specific nucleic acid probe under hybridizing conditions with either (i) test nucleic acid molecules isolated from said biological sample, or (ii) nucleic acid molecules synthesized from RNA molecules, wherein said probe recognizes at least a portion of nucleotide sequence of claim 1, and (b) detecting the formation of hybrids of said nucleic acid probe and (i) or (ii).

Within another related embodiment, methods are provided for detecting the presence of an *Fkh^{sf}*, or a mutant form thereof, in a biological sample, comprising the steps of: (a) contacting a biological sample with an anti-*Fkh^{sf}* antibody or an antibody fragment, wherein said contacting is performed under conditions that allow the binding of said antibody or antibody fragment to said biological sample, and (b) detecting any of said bound antibody or bound antibody fragment.

Within other aspects of the invention, methods are provided for introducing *Fkh^{sf}* nucleic acid molecules to an animal, comprising the step of administering a *Fkh^{sf}* nucleic acid molecule as described herein to an animal (e.g., a human, monkey, dog, cat, rat, or, mouse. Within one embodiment, the nucleic acid molecule is contained within and expressed by a viral vector (e.g., a vector generated at least in part from a retrovirus, adenovirus, adeno-associated virus, herpes virus, or, alphavirus). Within another embodiment the nucleic acid molecule is expressed by, or contained within a plasmid vector. Such vectors may be administered either *in vivo*, or *ex vivo* (e.g., to hematopoietic cells such as T cells).

Within other embodiments, transgenic non-human animals are provided wherein the cells of the animal express a transgene that contains a sequence encoding *Fkh^{sf}* protein.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures

or compositions (e.g., plasmids, etc.), and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a nucleotide sequence of mouse *Fkh^{sf}* cDNA (Sequence I.D. No. 1); translation is predicted to initiate at position 259 and terminate at position 1546.

Figure 2 depicts the amino acid sequence of mouse *Fkh^{sf}* (Sequence I.D. No. 2).

Figure 3 depicts a nucleotide sequence of 1735 bp corresponding to human *FKHsf* cDNA (Sequence I.D. No. 3; including a 1293 bp coding region); translation is predicted to initiate at position 55 and terminate at position 1348.

Figure 4 depicts the sequence of a 431 amino acid human *FKH^{sf}* protein (Sequence I.D. No. 4).

Figure 5 diagrammatically depicts a vector for generation of *FKH^{sf}* transgenic mice.

Figure 6 is a photograph which demonstrates that the *FKH^{sf}* transgene corrects the defect in scurfy animals.

Figure 7 is a graph which shows that *FKH^{sf}* tg mice have reduced lymph node cells, as compared to normal cells.

Figure 8 is a graph which shows that *FKH^{sf}* transgenic mice respond poorly to *in vitro* stimulation.

Figure 9 is a comparison of *FKH^{sf}* and JM2 cDNAs.

Figure 10 compares homology in various regions of human *FKH^{sf}* and murine *Fkh^{sf}*.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

Prior to setting forth the Invention in detail, it may be helpful to an understanding thereof to set forth definitions of certain terms and to list and to define the abbreviations that will be used hereinafter.

“Scurfy” refers to an inherited disease in mice which exhibit a severe lymphoproliferative disorder (*see, e.g.*, Lyon et al., *Proc. Natl. Acad. Sci. USA* 87:2433, 1990). The responsible gene (mutant forms of which are responsible for the disease) is shown in Sequence I.D. Nos. 1 and 3.

10 “Molecule” should be understood to include proteins or peptides (*e.g.*, antibodies, recombinant binding partners, peptides with a desired binding affinity), nucleic acids (*e.g.*, DNA, RNA, chimeric nucleic acid molecules, and nucleic acid analogues such as PNA), and organic or inorganic compounds.

“Nucleic acid” or “nucleic acid molecule” refers to any of
 15 deoxyribonucleic acid (DNA), ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acids can be composed of monomers that are naturally-occurring nucleotides (such as deoxyribonucleotides and ribonucleotides), or analogs of naturally-occurring
 20 nucleotides (*e.g.*, α -enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have modifications in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire
 25 sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages
 30 include phosphorothioate, phosphorodithioate, phosphoroselenoate,

5 “Isolated nucleic acid molecule” is a nucleic acid molecule that is not
integrated in the genomic DNA of an organism. For example, a DNA molecule that
encodes a gene that has been separated from the genomic DNA of a eukaryotic cell is an
isolated DNA molecule. Another example of an isolated nucleic acid molecule is a
chemically-synthesized nucleic acid molecule that is not integrated in the genome of an
10 organism.

“Promoter” is a nucleotide sequence that directs the transcription of a structural gene. Typically, a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter.

“Vector” refers to an assembly which is capable of directing the expression of desired protein. The vector must include transcriptional promoter elements which are operably linked to the genes of interest. The vector may be composed of either deoxyribonucleic acids (“DNA”), ribonucleic acids (“RNA”), or a combination of the two (*e.g.*, a DNA-RNA chimeric). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more selectable markers such as neomycin phosphotransferase or hygromycin phosphotransferase. Additionally, depending on the host cell chosen and the vector employed, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.

“Isolated” in the case of proteins or polypeptides, refers to molecules which are present in the substantial absence of other biological macromolecules, and appear nominally as a single band on SDS-PAGE gel with coomassie blue staining.

"Isolated" when referring to organic molecules means that the compounds are greater than 90% pure utilizing methods which are well known in the art (e.g., NMR, melting point).

"Cloning vector" refers to nucleic acid molecules, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell. Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites at which foreign nucleotide sequences can be inserted in a determinable fashion without loss of an essential biological function of the vector, as well as nucleotide sequences encoding a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance.

"Expression vector" refers to a nucleic acid molecule encoding a gene that is expressed in a host cell. Typically, gene expression is placed under the control of a promoter, and optionally, under the control of at least one regulatory element. Such a gene is said to be "operably linked to" the promoter. Similarly, a regulatory element and a promoter are operably linked if the regulatory element modulates the activity of the promoter.

"Recombinant host" refers to any prokaryotic or eukaryotic cell that contains either a cloning vector or expression vector. This term also includes those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned gene(s) in the chromosome or genome of the host cell.

In eukaryotes, RNA polymerase II catalyzes the transcription of a structural gene to produce mRNA. A nucleic acid molecule can be designed to contain an RNA polymerase II template in which the RNA transcript has a sequence that is complementary to that of a specific mRNA. The RNA transcript is termed an "anti-sense RNA" and a nucleic acid molecule that encodes the anti-sense RNA is termed an "anti-sense gene." Anti-sense RNA molecules are capable of binding to mRNA molecules, resulting in an inhibition of mRNA translation.

An "anti-sense oligonucleotide specific for *Fkh^{sf}*" or a "*Fkh^{sf}* anti-sense oligonucleotide" is an oligonucleotide having a sequence (a) capable of forming a stable

00696967-103500

triplex with a portion of the gene, or (b) capable of forming a stable duplex with a portion of an mRNA transcript. Similarly, an "anti-sense oligonucleotide specific for *Fkh^{sf}*" or a "*Fkh^{sf}* anti-sense oligonucleotide" is an oligonucleotide having a sequence (a) capable of forming a stable triplex with a portion of the *Fkh^{sf}* gene, or (b) capable of forming a stable duplex with a portion of an mRNA transcript of the *Fkh^{sf}* gene.

A "ribozyme" is a nucleic acid molecule that contains a catalytic center. The term includes RNA enzymes, self-splicing RNAs, self-cleaving RNAs, and nucleic acid molecules that perform these catalytic functions. A nucleic acid molecule that encodes a ribozyme is termed a "ribozyme gene."

10 Abbreviations: YAC, yeast artificial chromosome; PCR, polymerase chain reaction; RT-PCR, PCR process in which RNA is first transcribed into DNA at the first step using reverse transcriptase (RT); cDNA, any DNA made by copying an RNA sequence into DNA form. As utilized herein "*Fkh^{sf}*" refers to the gene product of the *Fkh^{sf}* gene (irrespective of whether the gene is obtained from humans, mammals, or
15 any other warm-blooded animal). When capitalized "*FKH^{sf}*" the gene product (and gene) should be understood to be derived from humans.

As noted above, the present invention relates generally to pharmaceutical products and methods and, more specifically, to methods and compositions useful for
20 diagnosing scurfy-related diseases, as well as methods for identifying compounds which can modulate the immune system.

Thus, as discussed in more detail below this discovery has led to the development of assays which may be utilized to select molecules which can act as agonists, or alternatively, antagonists of the immune system. Furthermore, such assays
25 may be utilized to identify other genes and gene products which are likewise active in modulating the immune system.

SCURFY

Briefly, the present inventions are based upon the unexpected discovery
30 that a mutation in the gene which encodes *Fkh^{sf}* results in rare condition (scurfy)

00595957.103500

characterized by a progressive lymphocytic infiltration of the lymph nodes, spleen, liver and skin resulting in gross morphological symptoms which include splenomegaly, hepatomegaly, greatly enlarged lymph nodes, runting, exfoliative dermatitis, and thickened malformed ears (Godfrey et al., *Amer. J. Pathol.* 138:1379, 1991; Godfrey et
 5 al., *Proc. Natl. Acad. Sci. USA* 88:5528, 1991). This new member of the winged-helix family represents a novel component of the immune system.

Methods which were utilized to discover the gene responsible for scurfy are provided below in Example 1. Methods for cloning the gene responsible for murine scurfy, as well as the human ortholog, are provided below in Examples 2 and 3.
 10 Methods for confirmation of gene identity and correlation with gene function, as determined using transgenic mice, are also provided in the Examples.

Also provided by the present invention are methods for determining the presence of *Fkh^{sf}* genes and gene products. Within one embodiment, such methods comprise the general steps of (a) contacting a *Fkh^{sf}* specific nucleic acid probe under
 15 hybridizing conditions with either (i) test nucleic acid molecules isolated from the biological sample, or (ii) nucleic acid molecules synthesized from RNA molecules, wherein the probe recognizes at least a portion of an *Fkh^{sf}* nucleotide sequence, and (b) detecting the formation of hybrids of said nucleic acid probe and (i) or (ii). A variety of methods may be utilized in order to amplify a selected sequence, including, for
 20 example, RNA amplification (see Lizardi et al., *Bio/Technology* 6:1197-1202, 1988; Kramer et al., *Nature* 339:401-402, 1989; Lomeli et al., *Clinical Chem.* 35(9):1826-1831, 1989; U.S. Patent No. 4,786,600), and nucleic acid amplification utilizing Polymerase Chain Reaction ("PCR") (see U.S. Patent Nos. 4,683,195, 4,683,202, and 4,800,159), reverse-transcriptase-PCR and CPT (see U.S. Patent Nos. 4,876,187, and
 25 5,011,769).

Alternatively, antibodies may be utilized to detect the presence of *Fkh^{sf}* gene products. More specifically, within one embodiment methods are provided for detecting the presence of an *Fkh^{sf}* peptide, or a mutant form thereof, in a biological sample, comprising the steps of (a) contacting a biological sample with an anti- *Fkh^{sf}*
 30 antibody or an antibody fragment, wherein said contacting is performed under

conditions that allow the binding of said antibody or antibody fragment to the biological sample, and (b) detecting any of the bound antibody or bound antibody fragment.

Such methods may be accomplished in a wide variety of assay formats including, for example, Countercurrent Immuno-Electrophoresis (CIEP),
 5 Radioimmunoassays, Radioimmunoprecipitations, Enzyme-Linked Immuno-Sorbent Assays (ELISA), Dot Blot assays, Inhibition or Competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual, supra*).

10 NUCLEIC ACID MOLECULES, PROTEINS, AND METHODS OF PRODUCING PROTEINS

Although various FKH^{sf} or Fkh^{sf} proteins and nucleic acid molecules (or portions thereof) have been provided herein, it should be understood that within the context of the present invention, reference to one or more of these proteins should be understood to include proteins of a substantially similar activity. As used herein,
 15 proteins are deemed to be "substantially similar" if: (a) they are encoded by a nucleotide sequence which is derived from the coding region of a gene which encodes the protein (including, for example, portions of the sequence or allelic variations of the sequence); (b) the nucleotide sequence is capable of hybridization to nucleotide sequences of the present invention under moderate, high or very high stringency (see
 20 Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1989), or has at least 50%, 60%, 70%, 75%, 80%, 90%, 95%, or greater homology to the sequences disclosed herein, or, (c) the DNA sequences are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b). Further, the nucleic acid molecule disclosed herein includes both complementary
 25 and non-complementary sequences, provided the sequences otherwise meet the criteria set forth herein. Within the context of the present invention, high stringency means standard hybridization conditions (e.g., 5XSSPE, 0.5% SDS at 65°C, or the equivalent). For purpose of hybridization, nucleic acid molecules which encode the amino-terminal domain, zinc finger domain, middle domain, or forkhead domain (see Example 10) may
 30 be utilized.

09696867.103500

The structure of the proteins encoded by the nucleic acid molecules described herein may be predicted from the primary translation products using the hydrophobicity plot function of, for example, P/C Gene or Intelligenetics Suite (Intelligenetics, Mountain View, California), or according to the methods described by

5 Kyte and Doolittle (*J. Mol. Biol.* 157:105-132, 1982).

Proteins of the present invention may be prepared in the form of acidic or basic salts, or in neutral form. In addition, individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions, or additions may be made to the amino acid or nucleic acid sequences, the net effect of

10 which is to retain or further enhance or decrease the biological activity of the mutant or wild-type protein. Moreover, due to degeneracy in the genetic code, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid sequence.

Other derivatives of the proteins disclosed herein include conjugates of

15 the proteins along with other proteins or polypeptides. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal fusion proteins which may be added to facilitate purification or identification of proteins (*see* U.S. Patent No. 4,851,341, *see also*, Hopp et al., *Bio/Technology* 6:1204, 1988.) Alternatively, fusion proteins (*e.g.*, FKH or Fkh-luciferase or FKH or Fkh-GFP) may be constructed in order

20 to assist in the identification, expression, and analysis of the protein.

Proteins of the present invention may be constructed using a wide variety of techniques described herein. Further, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the

25 resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific (or segment specific) mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary

30 methods of making the alterations set forth above are disclosed by Walder et al. (*Gene*

10 .Mutations which are made in the nucleic acid molecules of the present invention preferably preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, that would adversely affect translation of the mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed mutants screened for indicative biological activity. Alternatively, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following 20 ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion. Mutations may be introduced for purpose of preserving or increasing activity of the protein, or, for decreasing or disabling the protein (*e.g.*, mutant *Fkh*).

The present invention also provides for the manipulation and expression
30 of the above described genes by culturing host cells containing a vector capable of

expressing the above-described genes. Such vectors or vector constructs include either synthetic or cDNA-derived nucleic acid molecules encoding the desired protein, which are operably linked to suitable transcriptional or translational regulatory elements. Suitable regulatory elements may be derived from a variety of sources, including
 5 bacterial, fungal, viral, mammalian, insect, or plant genes. Selection of appropriate regulatory elements is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of regulatory elements include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a transcriptional terminator, and a ribosomal binding sequence, including a
 10 translation initiation signal.

Nucleic acid molecules that encode any of the proteins described above may be readily expressed by a wide variety of prokaryotic and eukaryotic host cells, including bacterial, mammalian, yeast or other fungi, viral, insect, or plant cells. Methods for transforming or transfecting such cells to express foreign DNA are well
 15 known in the art (*see, e.g.*, Itakura et al., U.S. Patent No. 4,704,362; Hinnen et al., *Proc. Natl. Acad. Sci. USA* 75:1929-1933, 1978; Murray et al., U.S. Patent No. 4,801,542; Upshall et al., U.S. Patent No. 4,935,349; Hagen et al., U.S. Patent No. 4,784,950; Axel et al., U.S. Patent No. 4,399,216; Goeddel et al., U.S. Patent No. 4,766,075; and Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring
 20 Harbor Laboratory Press, 1989; for plant cells see Czako and Marton, *Plant Physiol.* 104:1067-1071, 1994; and Paszkowski et al., *Biotech.* 24:387-392, 1992).

Bacterial host cells suitable for carrying out the present invention include *E. coli*, *B. subtilis*, *Salmonella typhimurium*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, as well as many other bacterial
 25 species well known to one of ordinary skill in the art. Representative examples of bacterial host cells include DH5 α (Stratagene, LaJolla, California).

Bacterial expression vectors preferably comprise a promoter which functions in the host cell, one or more selectable phenotypic markers, and a bacterial origin of replication. Representative promoters include the β -lactamase (penicillinase)
 30 and lactose promoter system (*see* Chang et al., *Nature* 275:615, 1978), the T7 RNA

polymerase promoter (Studier et al., *Meth. Enzymol.* 185:60-89, 1990), the lambda promoter (Elvin et al., *Gene* 87:123-126, 1990), the *trp* promoter (Nichols and Yanofsky, *Meth. in Enzymology* 101:155, 1983) and the *tac* promoter (Russell et al., *Gene* 20:231, 1982). Representative selectable markers include various antibiotic
 5 resistance markers such as the kanamycin or ampicillin resistance genes. Many plasmids suitable for transforming host cells are well known in the art, including among others, pBR322 (see Bolivar et al., *Gene* 2:95, 1977), the pUC plasmids pUC18, pUC19, pUC118, pUC119 (see Messing, *Meth. in Enzymology* 101:20-77, 1983 and Vieira and Messing, *Gene* 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and
 10 Bluescript M13 (Stratagene, La Jolla, California).

Yeast and fungi host cells suitable for carrying out the present invention include, among others, *Saccharomyces pombe*, *Saccharomyces cerevisiae*, the genera *Pichia* or *Kluyveromyces* and various species of the genus *Aspergillus* (McKnight et al., U.S. Patent No. 4,935,349). Suitable expression vectors for yeast and fungi include,
 15 among others, YCp50 (ATCC No. 37419) for yeast, and the amdS cloning vector pV3 (Turnbull, *Bio/Technology* 7:169, 1989), YRp7 (Struhl et al., *Proc. Natl. Acad. Sci. USA* 76:1035-1039, 1978), YEp13 (Broach et al., *Gene* 8:121-133, 1979), pJDB249 and pJDB219 (Beggs, *Nature* 275:104-108, 1978) and derivatives thereof.

Preferred promoters for use in yeast include promoters from yeast
 20 glycolytic genes (Hitzeman et al., *J. Biol. Chem.* 255:12073-12080, 1980; Alber and Kawasaki, *J. Mol. Appl. Genet.* 1:419-434, 1982) or alcohol dehydrogenase genes (Young et al., in *Genetic Engineering of Microorganisms for Chemicals*, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, *Meth. Enzymol.* 101:192-201, 1983). Examples of useful promoters for fungi vectors include those derived from
 25 *Aspergillus nidulans* glycolytic genes, such as the *adh3* promoter (McKnight et al., *EMBO J.* 4:2093-2099, 1985). The expression units may also include a transcriptional terminator. An example of a suitable terminator is the *adh3* terminator (McKnight et al., *ibid.*, 1985).

As with bacterial vectors, the yeast vectors will generally include a
 30 selectable marker, which may be one of any number of genes that exhibit a dominant

phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include *leu2* (Broach et al., *ibid.*), *ura3* (Botstein et al., *Gene* 8:17, 1979), or *his3* (Struhl et al.,
 5 *ibid.*). Another suitable selectable marker is the *cat* gene, which confers chloramphenicol resistance on yeast cells.

Techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (*ibid.*), Hinnen et al. (*Proc. Natl. Acad. Sci. USA* 75:1929-1933, 1978), Yelton et al. (*Proc. Natl. Acad. Sci. USA* 81:1740-1747,
 10 1984), and Russell (*Nature* 301:167-169, 1983). The genotype of the host cell may contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art.

Protocols for the transformation of yeast are also well known to those of
 15 ordinary skill in the art. For example, transformation may be readily accomplished either by preparation of spheroplasts of yeast with DNA (*see* Hinnen et al., *PNAS USA* 75:1929, 1978) or by treatment with alkaline salts such as LiCl (*see* Itoh et al., *J. Bacteriology* 153:163, 1983). Transformation of fungi may also be carried out using polyethylene glycol as described by Cullen et al. (*Bio/Technology* 5:369, 1987).

20 Viral vectors include those which comprise a promoter that directs the expression of an isolated nucleic acid molecule that encodes a desired protein as described above. A wide variety of promoters may be utilized within the context of the present invention, including for example, promoters such as MoMLV LTR, RSV LTR, Friend MuLV LTR, adenoviral promoter (Ohno et al., *Science* 265:781-784, 1994),
 25 neomycin phosphotransferase promoter/enhancer, late parvovirus promoter (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), Herpes TK promoter, SV40 promoter, metallothionein IIA gene enhancer/promoter, cytomegalovirus immediate early promoter, and the cytomegalovirus immediate late promoter. Within particularly preferred embodiments of the invention, the promoter is a tissue-specific promoter (*see*
 30 *e.g.*, WO 91/02805; EP 0,415,731; and WO 90/07936). Representative examples of

suitable tissue specific promoters include neural specific enolase promoter, platelet derived growth factor beta promoter, human alpha1-chimaerin promoter, synapsin I promoter and synapsin II promoter. In addition to the above-noted promoters, other viral-specific promoters (*e.g.*, retroviral promoters (including those noted above, as well
 5 as others such as HIV promoters), hepatitis, herpes (*e.g.*, EBV), and bacterial, fungal or parasitic (*e.g.*, malarial) -specific promoters may be utilized in order to target a specific cell or tissue which is infected with a virus, bacteria, fungus or parasite.

Mammalian cells suitable for carrying out the present invention include, among others: PC12 (ATCC No. CRL1721), N1E-115 neuroblastoma, SK-N-BE(2)C
 10 neuroblastoma, SHSY5 adrenergic neuroblastoma, NS20Y and NG108-15 murine cholinergic cell lines, or rat F2 dorsal root ganglion line, COS (*e.g.*, ATCC No. CRL 1650 or 1651), BHK (*e.g.*, ATCC No. CRL 6281; BHK 570 cell line (deposited with the American Type Culture Collection under accession number CRL 10314)), CHO (ATCC No. CCL 61), HeLa (*e.g.*, ATCC No. CCL 2), 293 (ATCC No. 1573; Graham
 15 et al., *J. Gen. Virol.* 36:59-72, 1977) and NS-1 cells. Other mammalian cell lines may be used within the present invention, including Rat Hep I (ATCC No. CRL 1600). Rat Hep II (ATCC No. CRL 1548), TCMK (ATCC No. CCL 139), Human lung (ATCC No. CCL 75.1), Human hepatoma (ATCC No. HTB-52), Hep G2 (ATCC No. HB 8065), Mouse liver (ATCC No. CCL 29.1), NCTC 1469 (ATCC No. CCL 9.1), SP2/0-
 20 Ag14 (ATCC No. 1581), HIT-T15 (ATCC No. CRL 1777), Jurkat (ATCC No. Tib 152) and RINm 5AHT₂B (Orskov and Nielson, *FEBS* 229(1):175-178, 1988).

Mammalian expression vectors for use in carrying out the present invention will include a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters include viral promoters and cellular promoters. Viral
 25 promoters include the cytomegalovirus immediate early promoter (Boshart et al., *Cell* 41:521-530, 1985), cytomegalovirus immediate late promoter, SV40 promoter (Subramani et al., *Mol. Cell. Biol.* 1:854-864, 1981), MMTV LTR, RSV LTR, metallothionein-1, adenovirus E1a. Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), a mouse V_K
 30 promoter (Bergman et al., *Proc. Natl. Acad. Sci. USA* 81:7041-7045, 1983; Grant et al.,

Nucl. Acids Res. 15:5496, 1987) and a mouse V_H promoter (Loh et al., *Cell* 33:85-93, 1983). The choice of promoter will depend, at least in part, upon the level of expression desired or the recipient cell line to be transfected.

Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, *ibid.*), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., *Nuc. Acids Res.* 9:3719-3730, 1981). The expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites. Preferred vectors may also include enhancer sequences, such as the SV40 enhancer. Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable expression vectors can be obtained from commercial sources (e.g., Stratagene, La Jolla, California).

Vector constructs comprising cloned DNA sequences can be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann et al., *EMBO J.* 1:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987). To identify cells that have stably integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. Other selectable markers include fluorescent proteins such as GFP (green fluorescent protein) or BFP (blue fluorescent protein). The selectable marker may be an amplifiable selectable marker. Preferred amplifiable selectable markers are the DHFR gene and the

neomycin resistance gene. Selectable markers are reviewed by Thilly (*Mammalian Cell Technology*, Butterworth Publishers, Stoneham, MA, which is incorporated herein by reference).

Mammalian cells containing a suitable vector are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable, selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells that satisfy these criteria can then be cloned and scaled up for production. Cells may also be selected for transfection based on their expression of GFP by sorting for GFP-positive cells using a flow cytometer.

Protocols for the transfection of mammalian cells are well known to those of ordinary skill in the art. Representative methods include calcium phosphate mediated transfection, electroporation, lipofection, retroviral, adenoviral and protoplast fusion-mediated transfection (*see* Sambrook et al., *supra*). Naked vector constructs can also be taken up by muscular cells or other suitable cells subsequent to injection into the muscle of a mammal (or other animals).

Numerous insect host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of baculoviruses as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (*Pestic. Sci.* 28:215-224,1990).

Numerous plant host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of *Agrobacterium rhizogenes* as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (*J. Biosci. (Bangalore)* 11:47-58, 1987).

Within related aspects of the present invention, proteins of the present invention, may be expressed in a transgenic animal whose germ cells and somatic cells

contain a gene which encodes the desired protein and which is operably linked to a promoter effective for the expression of the gene. Alternatively, in a similar manner transgenic animals may be prepared that lack the desired gene (*e.g.*, "knockout" mice). Such transgenics may be prepared in a variety non-human animals, including mice, rats, rabbits, sheep, dogs, goats and pigs (*see* Hammer et al., *Nature* 315:680-683, 1985, Palmiter et al., *Science* 222:809-814, 1983, Brinster et al., *Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985, Palmiter and Brinster, *Cell* 41:343-345, 1985, and U.S. Patent Nos. 5,175,383, 5,087,571, 4,736,866, 5,387,742, 5,347,075, 5,221,778, and 5,175,384). Briefly, an expression vector, including a nucleic acid molecule to be expressed together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs, for example, by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples. It is preferred that the introduced DNA be incorporated into the germ line of the animal so that it is passed on to the animal's progeny. Tissue-specific expression may be achieved through the use of a tissue-specific promoter, or through the use of an inducible promoter, such as the metallothionein gene promoter (Palmiter et al., 1983, *ibid*), which allows regulated expression of the transgene.

Animals which produce mutant forms of Fkh^{sf} other than the naturally occurring scurfy mutant ("sf"), or in genetic backgrounds different from the naturally occurring mutant, may be readily produced given the disclosure provided herein.

Proteins can be isolated by, among other methods, culturing suitable host and vector systems to produce the recombinant translation products of the present invention. Supernatants from such cell lines, or protein inclusions or whole cells where the protein is not excreted into the supernatant, can then be treated by a variety of purification procedures in order to isolate the desired proteins. For example, the supernatant may be first concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit. Following concentration, the concentrate may be applied to a suitable purification matrix such as, for example, an anti-protein antibody bound to a suitable support. Alternatively, anion or cation exchange resins may be employed in order to purify the

5 A protein is deemed to be “isolated” within the context of the present invention if no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by Coomassie blue staining. Within other embodiments, the desired protein can be isolated such that no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by silver staining.

10

15

20

30 also be used to identify interacting proteins. Such assays include ELISA, Western

blotting, co-immunoprecipitations, *in vitro* transcription/translation analysis and the like.

Within another aspect of the present invention, methods are provided for determining whether a selected molecule is capable of modulating the immune system, comprising the steps of (a) exposing a selected candidate molecule to cells which express *Fkh^{sf}*, or, mutant *Fkh^{sf}*, and (b) determining whether the molecule modulates the activity of *Fkh^{sf}*, and thereby determining whether said molecule can modulate the immune system. Cells for such tests may derive from (a) normal lymphocytes, (b) cell lines engineered to overexpress the FKH^{sf} (or Fkh^{sf}) protein (or mutant forms thereof) or (c) transgenic animals engineered to express said protein. Cells from such transgenic mice are characterized, in part, by a hyporesponsive state including diminished cell number and a decreased responsiveness to various stimuli (*e.g.*, Example 8).

It should be noted that while the methods recited herein may refer to the analysis of an individual test molecule, that the present invention should not be so limited. In particular, the selected molecule may be contained within a mixture of compounds. Hence, the recited methods may further comprise the step of isolating the desired molecule. Furthermore, it should be understood that candidate molecules can be assessed for their ability to modulate the immune system by a number of parameters, including for example, T-cell proliferation, cytokine production, and the like.

20

CANDIDATE MOLECULES

A wide variety of molecules may be assayed for their ability to modulate the immune system. Representative examples which are discussed in more detail below include organic molecules, proteins or peptides, and nucleic acid molecules.

25

1. Organic Molecules

Numerous organic molecules may be assayed for their ability to modulate the immune system. For example, within one embodiment of the invention suitable organic molecules may be selected either from a chemical library, wherein chemicals are assayed individually, or from combinatorial chemical libraries where

30

multiple compounds are assayed at once, then deconvoluted to determine and isolate the most active compounds.

Representative examples of such combinatorial chemical libraries include those described by Agrafiotis et al., "System and method of automatically
 5 generating chemical compounds with desired properties," U.S. Patent No. 5,463,564; Armstrong, R.W., "Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses," WO 95/02566; Baldwin, J.J. et al., "Sulfonamide derivatives and their use," WO 95/24186; Baldwin, J.J. et al., "Combinatorial dihydrobenzopyran library," WO 95/30642; Brenner, S., "New kit for
 10 preparing combinatorial libraries," WO 95/16918; Chenera, B. et al., "Preparation of library of resin-bound aromatic carbocyclic compounds," WO 95/16712; Ellman, J.A., "Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support," U.S. Patent No. 5,288,514; Felder, E. et al., "Novel combinatorial compound libraries," WO 95/16209; Lerner, R. et al., "Encoded combinatorial chemical libraries,"
 15 WO 93/20242; Pavia, M.R. et al., "A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library," WO 95/04277; Summerton, J.E. and D.D. Weller, "Morpholino-subunit combinatorial library and method," U.S. Patent No. 5,506,337; Holmes, C., "Methods for the Solid Phase Synthesis of Thiazolidinones, Metathiazanones, and Derivatives
 20 thereof," WO 96/00148; Phillips, G.B. and G.P. Wei, "Solid-phase Synthesis of Benzimidazoles," *Tet. Letters* 37:4887-90, 1996; Ruhland, B. et al., "Solid-supported Combinatorial Synthesis of Structurally Diverse β -Lactams," *J. Amer. Chem. Soc.* 111:253-4, 1996; Look, G.C. et al., "The Identification of Cyclooxygenase-1 Inhibitors from 4-Thiazolidinone Combinatorial Libraries," *Bioorg and Med. Chem.*
 25 *Letters* 6:707-12, 1996.

2. Proteins and Peptides

A wide range of proteins and peptides make likewise be utilized as candidate molecules for modulating the immune system.

a. Combinatorial Peptide Libraries

Peptide molecules which modulate the immune system may be obtained through the screening of combinatorial peptide libraries. Such libraries may either be prepared by one of skill in the art (see e.g., U.S. Patent Nos. 4,528,266 and 4,359,535, and Patent Cooperation Treaty Publication Nos. WO 92/15679, WO 92/15677, WO 90/07862, WO 90/02809, or purchased from commercially available sources (e.g., New England Biolabs Ph.D.TM Phage Display Peptide Library Kit).

b. Antibodies

Antibodies which modulate the immune system may readily be prepared given the disclosure provided herein. Within the context of the present invention, antibodies are understood to include monoclonal antibodies, polyclonal antibodies, anti-idiotypic antibodies, antibody fragments (e.g., Fab, and F(ab')₂, F_V variable regions, or complementarity determining regions). As discussed above, antibodies are understood to be specific against Fkh^{sf} if they bind with a K_a of greater than or equal to 10⁷M. preferably greater than or equal to 10⁸M. The affinity of a monoclonal antibody or binding partner, as well as inhibition of binding can be readily determined by one of ordinary skill in the art (see Scatchard, *Ann. N.Y. Acad. Sci.* 51:660-672, 1949).

Briefly, polyclonal antibodies may be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, various fowl, rabbits, mice, or rats. Typically, Fkh^{sf}, or a unique peptide thereof of 13-20 amino acids (preferably conjugated to keyhole limpet hemocyanin by cross-linking with glutaraldehyde) is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections, in conjunction with an adjuvant such as Freund's complete or incomplete adjuvant. Following several booster immunizations, samples of serum are collected and tested for reactivity to the protein or peptide. Particularly preferred polyclonal antisera will give a signal on one of these assays that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the protein, larger quantities of antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.

Monoclonal antibodies may also be readily generated using conventional techniques (see U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993 which are incorporated herein by reference; see also *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988, which are also incorporated herein by reference).

Other techniques may also be utilized to construct monoclonal antibodies (see William D. Huse et al., "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281, December 1989; see also L. Sastry et al., "Cloning of the Immunological Repertoire in *Escherichia coli* for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library," *Proc. Natl. Acad. Sci. USA* 86:5728-5732, August 1989; see also Michelle Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," *Strategies in Molecular Biology* 3:1-9, January 1990).

A wide variety of assays may be utilized to determine the presence of antibodies which are reactive against the Fkh^{sf} (or the mutant forms of Fkh^{sf} described herein), including for example countercurrent immuno-electrophoresis, radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, western blots, immunoprecipitation, Inhibition or Competition Assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988).

Once suitable antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns. or any combination of these techniques.

5

c. Mutant *Fkh^{sf}*

10

15

3. Nucleic Acid Molecules

20

30

“ribozymes” are intended to include RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity. The catalytic strand cleaves a specific site in a target RNA at greater than stoichiometric concentration. A wide variety of ribozymes may be utilized within the context of the present invention, including for example, the hammerhead ribozyme (for example, as described by Forster and Symons, *Cell* 48:211-220, 1987; Haseloff and Gerlach, *Nature* 328:596-600, 1988; Walbot and Bruening, *Nature* 334:196, 1988; Haseloff and Gerlach, *Nature* 334:585, 1988); the hairpin ribozyme (for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al., European Patent Publication No. 0 360 257, published March 26, 1990); and Tetrahymena ribosomal RNA-based ribozymes (see Cech et al., U.S. Patent No. 4,987,071). Ribozymes of the present invention typically consist of RNA, but may also be composed of DNA, nucleic acid analogs (e.g., phosphorothioates), or chimerics thereof (e.g., DNA/RNA/RNA).

4. Labels

FKH^f or *Fkh^f*, (as well as mutant forms thereof), or, any of the candidate molecules described above and below, may be labeled with a variety of compounds, including for example, fluorescent molecules, toxins, and radionuclides. Representative examples of fluorescent molecules include fluorescein, *Phycobili* proteins, such as phycoerythrin, rhodamine, Texas red and luciferase. Representative examples of toxins include ricin, abrin diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, *Shigella* toxin, and *Pseudomonas* exotoxin A. Representative examples of radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I-131, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. In addition, the antibodies described above may also be labeled or conjugated to one partner of a ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein.

Methods for conjugating or labeling the molecules described herein with the representative labels set forth above may be readily accomplished by one of ordinary skill in the art (see Trichothecene Antibody Conjugate. U.S. Patent No.

4,744,981; Antibody Conjugate, U.S. Patent No. 5,106,951; Fluorogenic Materials and Labeling Techniques, U.S. Patent No. 4,018,884; Metal Radionuclide Labeled Proteins for Diagnosis and Therapy, U.S. Patent No. 4,897,255; and Metal Radionuclide Chelating Compounds for Improved Chelation Kinetics, U.S. Patent No. 4,988,496; see
5 also Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wilchek (eds.), Academic Press, New York, p. 30, 1974; see also Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988).

10

PHARMACEUTICAL COMPOSITIONS

As noted above, the present invention also provides a variety of pharmaceutical compositions, comprising one of the above-described molecules which modulates the immune system, along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be nontoxic to
15 recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered
20 saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents. Preferably, the pharmaceutical composition (or, 'medicament') is provided in sterile, pyrogen-free form.

In addition, the pharmaceutical compositions of the present invention may be prepared for administration by a variety of different routes. In addition,
25 pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients or diluents (e.g., water, saline or PBS) which
30 may be necessary to reconstitute the pharmaceutical composition.

METHODS OF TREATMENT

The present invention also provides methods for modulating the immune system. Through use of the molecules described herein which modulate the immune system, a wide variety of conditions in warm blooded animals may be readily treated or prevented. Examples of warm-blooded animals that may be treated include both vertebrates and mammals, including for example humans, horses, cows, pigs, sheep, dogs, cats, rats and mice. Such methods may have therapeutic value in patients with altered immune systems. This would include such patients as those undergoing chemotherapy of those with various immunodeficiency syndromes, as well as patients with a T cell mediated autoimmune disease. Therapeutic value may also be recognized from utility as a vaccine adjuvant.

Therapeutic molecules, depending on the type of molecule, may be administered via a variety of routes in a variety of formulations. For example, within one embodiment organic molecules may be delivered by oral or nasal routes, or by injection (e.g., intramuscularly, intravenously, and the like).

Within one aspect, methods are provided for modulating the immune system, comprising the step of introducing into lymphoid cells a vector which directs the expression of a molecule which modulates the immune system, and administering the vector containing cells to a warm-blooded animal. Within other related embodiments, the vector may be directly administered to a desired target location (e.g., the bone marrow).

A wide variety of vectors may be utilized for such therapeutic purposes, including both viral and non-viral vectors. Representative examples of suitable viral vectors include herpes viral vectors (e.g., U.S. Patent No. 5,288,641), adenoviral vectors (e.g., WO 94/26914, WO 93/9191 WO 99/20778; WO 99/20773; WO 99/20779; Kolls et al., *PNAS* 91(1):215-219, 1994; Kass-Eisler et al., *PNAS* 90(24):11498-502, 1993; Guzman et al., *Circulation* 88(6):2838-48, 1993; Guzman et al., *Cir. Res.* 73(6):1202-1207, 1993; Zabner et al., *Cell* 75(2):207-216, 1993; Li et al., *Hum Gene Ther.* 4(4):403-409, 1993; Caillaud et al., *Eur. J. Neurosci.* 5(10):1287-1291, 1993; Vincent

5

15

2

5

way of limitation.

EXAMPLESEXAMPLE 1

5 IDENTIFICATION OF THE GENE RESPONSIBLE FOR THE SCURFY MUTANT

A. Cloning of a Scurfy gene

The original *scurfy* mutation arose spontaneously in the partially inbred MR stock at Oak Ridge National Laboratory (ORNL) in 1949. Backcross analysis was
 10 used to fine map the peri-centromeric region of the X chromosome containing the mouse Scurfy mutation. A physical map covering the same region was generated concurrently through the isolation of overlapping yeast and bacterial artificial chromosomes (YACs and BACs). Once the candidate region was narrowed down to
 ~500 kilobase pairs (kb), large-scale DNA sequencing was performed on 4 overlapping
 15 BAC clones. All the transcription units in this 500 kb region were identified through a combination of sequence database searching and the application of computer exon prediction programs. Candidate genes were then screened for Scurfy-specific mutations by comparing the sequences of cDNAs obtained by the Reverse Transcription-Polymerase Chain Reaction (RT-PCR) procedure from normal and Scurfy-derived RNA
 20 samples. In one gene, referred to here as *Fkh^f*, a two base pair (bp) insertion was found in the coding region of the Scurfy cDNA, relative to the normal cDNA. The insertion was confirmed by comparing the DNA sequences of PCR products derived from the genomic DNA of several mouse strains, including the Scurfy mutant. Again, the two bp insertion was found only in the Scurfy sample, establishing this as the probable cause of
 25 the Scurfy defect.

The mouse *Fkh^f* gene is contained within the BAC clone 8C22, and has been completely sequenced. It spans ~14 kb and contains 11 coding exons. The locations of exon breaks were initially identified by computer analysis of the genomic DNA sequence, using the GenScan exon prediction program; exon locations were then

confirmed by direct comparison of cDNA sequences derived from normal mouse tissues to the genomic sequence.

The length of cDNA obtained is 2160 bp; the coding region spans 1287 bp of that, encoding a protein of 429 amino acids. Figure 1 shows the nucleotide
 5 sequence of the mouse *Fkh^{sf}* cDNA; translation is predicted to initiate at position 259 and terminate at position 1546. Figure 2 shows the amino acid sequence of mouse *Fkh^{sf}*.

b. Generation of *Fkh^{sf}* transgenic mice.

10 The identity of the *Fkh^{sf}* gene as the true cause of the Scurfy phenotype was confirmed in transgenic mice. Briefly, a 30 kb fragment of the normal genomic DNA, including the ~7 kb coding region of the *Fkh^{sf}* gene, as well as ~20 kb of upstream flanking sequences and ~4 kb of downstream sequences (Figure 5) was
 15 microinjected into normal mouse one-cell embryos. Five individual founder animals were generated, each with distinct integrations, and a male animal from each transgenic line was crossed to a female *sf* carriers. Male offspring carrying both the transgene (normal *Fkh^{sf}*) and *sf* mutation (mutant *Fkh^{sf}*) were analyzed.

Analysis consisted of examination of animals for runting, scaly skin, fur abnormalities and other hallmarks of the scurfy phenotype. In addition, lymphoid
 20 tissues (thymus, spleen and nodes) were harvested and their size and cell number examined and compared to both normal animals as well as scurfy mice. For all five transgenic lines, male *sf* progeny that carried the transgene were normal in size and weight and appeared healthy in all respects. Lymph node size in these transgenic mice was similar to (or smaller than) that of normal animals (Figure 6) and there was no sign
 25 of activated T cells. These parameters are extremely different from *sf* mice and indicate that addition of the normal *Fkh^{sf}* gene can overcome the defect found in scurfy mice, thus confirming that the mutation in the *Fkh^{sf}* gene is the cause of Scurfy disease.

EXAMPLE 2GENERATION OF *FKH^{SF}* cDNA

A complementary DNA (cDNA) encoding the complete mouse *Fkh^{SF}* protein may be obtained by a reverse-transcriptase polymerase chain reaction (RT-PCR) procedure. More specifically, first-strand cDNA is generated by oligo dT priming 5 ug of total RNA from a suitable source (eg., mouse spleen) and extending with reverse transcriptase under standard conditions (eg., Gibco/BRL SuperScript kit). An aliquot of the first-strand cDNA is then subjected to 35 cycles of PCR (94°C for 30 sec, 63°C for 30 sec, 72°C for 2 min) in the presence of the forward and reverse primers (Forward primer: GCAGATCTCC TGACTCTGCC TTC; Reverse primer: GCAGATCTGA CAAGCTGTGT CTG) (0.2 mM final concentration), 60 mM Tris-HCl, 15 mM ammonium sulfate, 1.5 mM magnesium chloride, 0.2 mM each dNTP and 1 unit of Taq polymerase.

EXAMPLE 3GENERATION OF THE HUMAN ORTHOLOG TO MURINE *FKH^{SF}*

A human *FKH^{SF}* cDNA encoding the complete *FKH^{SF}* protein may be obtained by essentially the same procedure as described in Example 2. In particular, starting with total spleen RNA, and utilizing the following oligonucleotide primers (Forward primer: AGCCTGCCCT TGGACAAGGA C; Reverse primer: GCAAGACAGT GGAAACCTCA C), and the same PCR conditions outlined above, except with a 60°C annealing temperature.

Figure 4 shows the nucleotide sequence of the 1869 bp cDNA obtained to date (including an 1293 bp coding region); translation is predicted to initiate at position 189 and terminate at position 1482. Figure 4 shows the sequence of the 431 amino acid human *FKH^{SF}* protein. Comparison of the predicted coding region of the human gene to the mouse cDNA sequence reveals nearly identical exon structure and 86.1% amino acid sequence identity across the entire protein.

EXAMPLE 4

METHODS FOR DETECTING SCURFY MUTATIONS

As noted above, the Scurfy mutation was originally discovered by
5 directly sequencing cDNAs derived by RT-PCR of *sf* and normal mouse RNA samples,
and confirmed by sequencing the same region from genomic DNA. The nature of the
mutation (*i.e.*, a 2 bp insertion) lends itself to a number of different mutation detection
assays. The first is based on differential hybridization of oligonucleotide probes. Such
a hybridization-based assay could allow quantitative analysis of allele-specific
10 expression.

As an example, a 360 bp DNA fragment is amplified from 1st strand
cDNA using the following oligos:

DMO5985 (forward): CTACCCACTGCTGGCAAATG (ntd. 825-844 of Figure. 1)

DMO6724 (reverse): GAAGGAACTATTGCCATGGCTTC (ntd 1221-1199)

20 The PCR products are run on an 1.8% agarose gel, transferred to nylon
membrane and probed with end-labeled oligonucleotides that are complementary to the
region corresponding to the site of the Scurfy-specific 2 bp insertion. Two separate
hybridization reactions are performed to detect the normal and Scurfy PCR products,
using the oligonucleotides below (the site of the 2 bp insertion is shown in bold):

25 Normal: ATGCAGCAAGAGCTCTTGTCCATTGAGG

DMO7439

Scurfy: GCAGCAAGAGCTCTTTTGTCCATTGAGG

30 DMO6919

The Scurfy mutation can also be detected by a cold Single-Strand Conformation Polymorphism (cSSCP) assay. In this assay, the same PCR products described above are run on 20% acrylamide (TBE) gels after strand denaturation. The Scurfy insertion causes a shift in strand mobility, relative to the normal sequence, and the separate strands are detected after staining with ethidium bromide.

EXAMPLE 5

FKH^{SF} GENE EXPRESSION

10

Semi-quantitative RT-PCR has been used to analyze the pattern of mouse and human *Fkh^{SF}* gene expression in a wide variety of tissues and cell lines. Levels of expression are normalized to the ubiquitously expressed DAD-1 gene. In short, the *Fkh^{SF}* gene is expressed, albeit at very low levels, in nearly every tissue examined thus far, including thymus, spleen, sorted CD4⁺ and CD4-CD8⁻ T-lymphocytes, as well as kidney, brain, and various mouse and human T-cell lines and human tumors. Absence of expression, however, was noted in freshly sorted mouse B-cells.

As expected, no differences in level of expression were observed in normal vs. Scurfy tissues in the RT-PCR assays.

20

EXAMPLE 6

IN VITRO EXPRESSION OF *FKH^{SF}*

25

Full-length mouse and human *Fkh^{SF}* cDNAs, as well as various sub-regions of the cDNAs are cloned into vectors which allow expression in mammalian cells (such as the human Jurkat T-cell line), *E. coli* or yeast. The *E. coli* or yeast systems can be used for production of protein for the purpose of raising *Fkh^{SF}*-specific antibodies (see below).

30

EXAMPLE 7GENERATION OF ANTI-FKH^{sf} ANTIBODIES

Protein expressed from vectors described in example 6 are used to
 5 immunize appropriate animals for the production of FKH^{sf} specific antibodies. Either
 full length or truncated proteins can be used for this purpose. Protein can be obtained,
 for example, from bacteria such as *E. coli*, insect cells or mammalian cells. Animal
 species can include mouse, rabbit, guinea pig, chicken or other. Rabbit antisera specific
 for FKH^{sf} has been generated, as determined by biochemical characterization
 10 (immunoprecipitation and western blotting).

EXAMPLE 8ASSAY FOR FUNCTION OF AN FKH^{sf} GENE

15 Since loss of function of the FKH^{sf} protein results in the phenotype
 observed in scurfy animals (wasting, hyperactive immune responsiveness and death),
 assays are described for assessing excessive expression of the FKH^{sf} protein.
 Transgenic animals (described in Example 1) are examined for their state of immune
 competence, using several different parameters. Animals are examined for the number
 20 of lymphoid cells present in lymph nodes and thymus (Figure 7) as well as the
 responsiveness of T cells to in vitro stimulation (Figure 8).

Scurfy mutant animals have roughly twice as many cells in their lymph
 nodes as normal animals, whereas mice which express excess levels of the normal
 FKH^{sf} protein contain roughly one-third as many cells (Figure 7). Further, the number
 25 of thymocytes is normal (Figure 7) as is their cell surface phenotype as assessed by flow
 cytometry using standard antisera (not shown), indicating that there is no developmental
 defect associated with excess FKH^{sf} protein.

Normal, scurfy and transgenic animals are further examined for their
 proliferative responses to T cell stimulation. CD4⁺ T cells are reacted with antibodies
 30 to CD3 and CD28 and their proliferative response measured using radioactive

thymidine incorporation. Whereas only scurfy cells divide in the absence of stimulation, normal cells respond well following stimulation. FKH^{sf} transgenic cells also respond to stimulation, however the response is significantly less than that of normal cells (Figure 8). This indicates that CD4+ T cells that express excess FKH^{sf} have a diminished capacity to respond to stimuli.

EXAMPLE 9HUMAN FKH^{sf} cDNA SEQUENCE IS RELATED TO JM2

A modified version of the human *FKH^{sf}* cDNA sequence exists in the
 5 GenBank public sequence database. This sequence is called JM2 (GenBank acc. #
 AJ005891), and is the result of the application of exon prediction programs to the
 genomic sequence containing the *FKH^{sf}* gene (Strom, T.M. et al., *unpublished* – see
 GenBank acc. # AJ005891). In contrast, the structure of the *FKH^{sf}* cDNA was
 determined experimentally. The GAP program of the Genetics Computer Group (GCG;
 10 Madison, USA) Wisconsin sequence analysis package was used to compare the two
 sequences, and the differences are illustrated in Figure 9. The 5' ends of the two
 sequences differ in their location within the context of the genomic DNA sequence, the
 second coding exon of *FKH^{sf}* is omitted from JM2, and the last intron of the *FKH^{sf}* gene
 is unspliced in the JM2 sequence. These differences result in a JM2 protein with a
 15 shorter amino-terminal domain, relative to FKH^{sf}, and a large insertion within the
 forkhead domain (see below) at the carboxy-terminus.

EXAMPLE 10The FKH^{sf} protein is conserved across species

20

The FKH^{sf} protein can be divided into sub-regions, based on sequence
 motifs that may indicate functional domains. The two principal motifs in FKH^{sf} are the
 single zinc finger (ZNF) of the C₂H₂ class in the middle portion of the protein, and the
 forkhead, or winged-helix domain at the extreme carboxy-terminus of the protein. For
 25 the purposes of characterizing the degree of homology between FKH^{sf} and other
 proteins, we have split the protein up into four regions:

Amino-terminal domain:	residues 1-197 of Figure 2
	residues 1-198 of Figure 4

30

Zinc finger domain: residues 198-221 of Figure 2
residues 199-222 of Figure 4

5 Middle domain: residues 222-336 of Figure 2
residues 223-336 of Figure 4

Forkhead domain: residues 337-429 of Figure 2
residues 337-431 of Figure 4

10 Using the Multiple Sequence Alignment program from the DNASTar sequence analysis package, the Lipman-Pearson algorithm was employed to determine the degree of similarity between the human FKH^{sf} and mouse Fkh^{sf} proteins across these four domains. The results are shown in Figure 10. The similarity indices ranged from 82.8% to 96.4%, indicating that this protein is very highly conserved across species.

15

EXAMPLE 11

IDENTIFICATION OF NOVEL FKH^{sf}-RELATED GENES

The unique features of the *FKH^f* gene sequence may be used to identify
20 other novel genes (and proteins) which fall into the same sub-class of forkhead-containing molecules. The FKH^{sf} protein is unique in its having a single zinc finger domain amino-terminal to the forkhead domain as well as in the extreme carboxy-terminal position of the forkhead domain. A degenerate PCR approach may be taken to isolate novel genes containing a zinc finger sequence upstream of a forkhead domain.
25 By way of example, the following degenerate primers were synthesized (positions of degeneracy are indicated by parentheses, and "I" indicates the nucleoside inosine):

Forward primer: CA(TC)GGIGA(GA)TG(CT)AA(GA)TGG

Reverse primer: (GA)AACCA(GA)TT(AG)TA(AGT)AT(CT)TC(GA)TT

30

The forward primer corresponds to a region within the zinc finger sequence and the reverse primer corresponds to a region in the middle of the forkhead domain. These primers were used to amplify first-strand cDNA produced as in Example 2 from a variety of human tissues (including liver, spleen, brain, lung, kidney, etc.). The following PCR conditions were used: forward and reverse primers at 0.2 mM final concentration, 60 mM Tris-HCl, 15 mM ammonium sulfate, 1.5 mM magnesium chloride, 0.2 mM each dNTP and 1 unit of Taq polymerase, subjected to 35 cycles (94°C for 30 sec, 50°C for 30 sec, 72°C for 2 min). PCR products were visualized on a 1.8% agarose gel (run in 1x TAE) and sub-cloned into the TA cloning vector (Invitrogen, Carlsbad, CA); individual clones were sequenced and used for further characterization of full-length cDNAs.

Alternatively, the unique regions of the *FKH^f* gene (i.e., the "Amino-terminal" and "Middle" domains) may be used to screen cDNA libraries by hybridization. cDNA libraries, derived from a variety of human and/or mouse tissues, and propagated in lambda phage vectors (eg., lambda gt11) were plated on agarose, plaques were transferred to nylon membranes and probed with fragments derived from the unique regions of the *FKH^f* gene. Under high stringency conditions (eg., hybridization in 5x SSPE, 5x Denhardt's solution, 0.5% SDS at 65°C, washed in 0.1x SSPE, 0.1% SDS at 65°C) only very closely related sequences are expected to hybridize (i.e., 90-100% homologous). Under lower stringency, such as hybridization and washing at 45°-55°C in the same buffer as above, genes that are related to *FKH^f* (65-90% homologous) may be identified. Based on results obtained from searching public databases with the unique sequences of *FKH^{sf}* any genes identified through low- to mid-stringency hybridization experiments are expected to represent novel members of a "*FKH^{sf}* family".

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. An isolated nucleic acid molecule which encodes Fkh^{sf}.
2. The isolated nucleic acid molecule according to claim 1, wherein said Fkh^{sf} is murine Fkh^{sf}
3. The isolated nucleic acid molecule according to claim 1, wherein said Fkh^{sf} is human FKH^{sf}
4. The isolated nucleic acid molecule according to claim 1, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule that encodes an amino acid sequence comprising SEQ ID NOS 2, or, 4, (b) a nucleic acid molecule that hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS: 1, or, 3, or its complement, and (c) a nucleic acid molecule that encodes a functional fragment of the polypeptide encoded by either (a) or (b).
5. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes the amino acid sequence of SEQ ID NO:2.
6. The isolated nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:1.
7. A vector comprising the isolated nucleic acid molecule of claim 1.
8. The vector according to claim 7 wherein said vector is a viral vector.

9. The vector according to claim 8 wherein said viral vector is generated from a virus selected from the group consisting of retrovirus, adenovirus, herpes virus, adeno-associated virus and alphavirus.

10. An expression vector comprising the isolated nucleic acid molecule of claim 1 and a promoter, wherein said promoter is operably linked with said nucleic acid molecule.

11. A recombinant host cell comprising the expression vector of claim 10.

12. A method of using the expression vector of claim 10 to prepare Fkh^{sf} protein, said method comprising the steps of:

- (a) culturing recombinant host cells that comprise said expression vector and that produce said protein, and
- (b) isolating said protein from said cultured recombinant host cells.

13. An isolated polypeptide comprising an amino acid sequence encoded by the nucleic acid molecule according to anyone of claims 1 to 6.

14. An antibody or antibody fragment that binds specifically with the polypeptide encoded by the nucleic acid molecule according to claim 1.

15. The antibody of claim 13, wherein said antibody is selected from the group consisting of:

- (a) polyclonal antibody,
- (b) murine monoclonal antibody,
- (c) humanized antibody derived from (b), and
- (d) human monoclonal antibody.

16. The antibody fragment of claim 14, wherein said antibody fragment is selected from the group consisting of $F(ab')_2$, $F(ab)_2$, Fab' , Fab , Fv , sFv , and minimal recognition unit.

17. A fusion protein comprising the polypeptide according to claim 13.

18. A method of detecting the presence of a Fkh^{sf} nucleic acid sequence in a biological sample from a subject, comprising the steps of :

- (a) contacting a Fkh^{sf} specific nucleic acid probe under hybridizing conditions with either (i) test nucleic acid molecules isolated from said biological sample, or (ii) nucleic acid molecules synthesized from RNA molecules, wherein said probe recognizes at least a portion of nucleotide sequence of claim 1, and
- (b) detecting the formation of hybrids of said nucleic acid probe and (i) or (ii).

19. The method according to claim 18, wherein said test nucleic acid molecule is obtained by RT-PCR.

20. A method of detecting the presence of an Fkh^{sf} , or a mutant form thereof, in a biological sample, comprising the steps of:

- (a) contacting said biological sample with an anti- Fkh^{sf} antibody or an antibody fragment, wherein said contacting is performed under conditions that allow the binding of said antibody or antibody fragment to said biological sample, and
- (b) detecting any of said bound antibody or bound antibody fragment.

21. The method of claim 20, wherein said antibody or said antibody fragment is selected from the group consisting of:

- (a) polyclonal antibody,
- (b) a murine monoclonal antibody,
- (c) a humanized antibody derived from (b),

22. The method of claim 20, wherein said antibody fragment is selected from the group consisting of F(ab')₂, F(ab)₂, Fab', Fab, Fv, sFv, and minimal recognition unit.

24. An isolated oligonucleotide which is capable of hybridizing to the nucleic acid molecule according to claim 1.

26. A method of introducing a *Fkh^{sf}* nucleic acid molecule to an animal, comprising the step of administering a *Fkh^{sf}* nucleic acid molecule according to claim 1 to an animal.

28. The method according to claim 26 wherein said nucleic acid molecule is expressed by a plasmid vector.

30. The method according to claim 26 wherein said nucleic acid molecule is administered to cells ex vivo, and said cells are then administered to said animal.

31. The method according to claim 26 wherein said cells are hematopoietic cells.

32.

33.

34.

ABSTRACT OF THE DISCLOSURE

Isolated nucleic acid molecules are provided which encode Fkh^{sf}, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic acid sequences disclosed herein (as well as mutant forms thereof), numerous molecules may be identified which modulate the immune system.

MOUSE *Fkh^{sf}* cDNA SEQUENCE

```

1  GCTGATCCCC CTCTAGCAGT CCACTTCACC AAGGTGAGCG AGTGTCCCTG
51  CTCTCCCCCA CCAGACACAG CTCTGCTGGC GAAAGTGGCA GAGAGGTATT
101 GAGGGTGGGT GTCAGGAGCC CACCAGTACA GCTGGAAACA CCCAGCCACT
151 CCAGCTCCCG GCAACTTCTC CTGACTCTGC CTTCAGACGA GACTTGGAAG
201 ACAGTCACAT CTCAGCAGCT CCTCTGCCGT TATCCAGCCT GCCTCTGACA
251 AGAACCCAAT GCCCAACCCT AGGCCAGCCA AGCCTATGGC TCCTTCCTTG
301 GCCCTTGGCC CATCCCCAGG AGTCTTGCCA AGCTGGAAGA CTGCACCCAA
351 GGGCTCAGAA CTTCTAGGGA CCAGGGGCTC TGGGGGACCC TTCCAAGGTC
401 GGGACCTGCG AAGTGGGGCC CACACCTCTT CTTCTTGAA CCCCTTGCCA
451 CCATCCCAGC TGCAGCTGCC TACAGTGCCC CTAGTCATGG TGGCACCGTC
501 TGGGGCCCGA CTAGGTCCCT CACCCACCTT ACAGGCCCTT CTCCAGGACA
551 GACCACACTT CATGCATCAG CTCTCCACTG TGGATGCCCC TGCCAGACC
601 CCTGTGCTCC AAGTGCCTCC ACTGGACAAC CCAGCCATGA TCAGCCTCCC
651 ACCACCTTCT GCTGCCACTG GGGTCTTCTC CCTCAAGGCC CGGCCTGGCC
701 TGCCACCTGG GATCAATGTG GCCAGTCTGG AATGGGTGTC CAGGGAGCCA
751 GCTCTACTCT GCACCTTCCC ACGCTCGGGT ACACCCAGGA AAGACAGCAA
801 CCTTTTGGCT GCACCCCAAG GATCCTACCC ACTGCTGGCA AATGGAGTCT
851 GCAAGTGGCC TGGTTGTGAG AAGGTCTTCG AGGAGCCAGA AGAGTTTCTC
901 AAGCACTGCC AAGCAGATCA TCTCCTGGAT GAGAAAGGCA AGGCCAGTG
951 CCTCCTCCAG AGAGAAGTGG TGCAGTCTCT GGAGCAGCAG CTGGAGCTGG
1001 AAAAGGAGAA GCTGGGAGCT ATGCAGGCCC ACCTGGCTGG GAAGATGGCG
1051 CTGGCCAAGG CTCCATCTGT GGCCTCAATG GACAAGAGCT CTTGCTGCAT
1101 CGTAGCCACC AGTACTCAGG GCAGTGTGCT CCCGGCCTGG TCTGCTCCTC
1151 GGGAGGCTCC AGACGGCGGC CTGTTTGCAG TCGGAGGCA CCTCTGGGGA
1201 AGCCATGGCA ATAGTTCCTT CCCAGAGTTC TTCCACAACA TGGACTACTT
1251 CAAGTACCAC AATATGCGAC CCCCTTTCAC CTATGCCACC CTTATCCGAT
1301 GGGCCATCCT GGAAGCCCCG GAGAGGCAGA GGACACTCAA TGAAATCTAC
1351 CATTGGTTTA CTCGCATGTT CGCCTACTTC AGAAACCACC CCGCCACCTG
1401 GAAGAATGCC ATCCGCCACA ACCTGAGCCT GCACAAGTGC TTTGTGCGAG
1451 TGGAGAGCGA GAAGGGAGCA GTGTGGACCG TAGATGAATT TGAGTTTCGC
1501 AAGAAGAGGA GCCAACGCCC CAACAAGTGC TCCAATCCCT GCCCTTGACC
1551 TCAAAACCAA GAAAAGGTGG GCGGGGGAGG GGGCCAAAAC CATGAGACTG
1601 AGGCTGTGGG GGCAAGGAGG CAAGTCCTAC GTGTACCTAT GGAAACCGGG
1651 CGATGATGTG CCTGCTATCA GGGCCTCTGC TCCCTATCTA GCTGCCCTCC
1701 TAGATCATAT CATCTGCCTT ACAGCTGAGA GGGGTGCCAA TCCCAGCCTA
1751 GCCCCTAGTT CCAACCTAGC CCCAAGATGA ACTTTCCAGT CAAAGAGCCC
1801 TCACAACCAG CTATACATAT CTGCCTTGGC CACTGCCAAG CAGAAAGATG
1851 ACAGACACCA TCCTAATATT TACTCAACCC AAACCCTAAA ACATGAAGAG
1901 CCTGCCTTGG TACATTCGTG AACTTTCAAA GTTAGTCATG CAGTCACACA
1951 TGA CTG CAGT CCTACTGACT CACACCCCAA AGCACTCACC CACAACATCT
2001 GGAACCACGG GCACTATCAC ACATAGGTGT ATATACAGAC CCTTACACAG
2051 CAACAGCACT GGAACCTTCA CAATTACATC CCCCCAAACC ACACAGGCAT
2101 AACTGATCAT ACGCAGCCTC AAGCAATGCC CAAAATACAA GTCAGACACA
2151 GCTTGTCAGA

```

Figure 1

MOUSE Fkh^{sf} PROTEIN SEQUENCE

1 MPNPRPAKPM APSLALGPSP GVLPSWKTAP KGSELLGTRG SGGPFQGRDL
51 RSGAHTSSSL NPLPPSQLQL PTVPLVMVAP SGARLGPSPH LQALLQDRPH
101 FMEQLSTVDA HAQTPVLQVR PLDNPAMISL PPPSAATGVF SLKARPGLPP
151 GINVASLEWV SREPALLCTF PRSGTPRKDS NLLAAPQGSY PLLANGVCKW
201 PGCEKVFEED EEFLKHCQAD HLLDEKGKAQ CLLQREVVQS LEQQLELEKE
251 KLGAMQAHLA GKMALAKAPS VASMDKSSCC IVATSTQGSV LPAWSAPREA
301 PDGGLFAVRR HLWGSHGNSS FPEFFHNMDY FKYHNMRRPF TYATLIRWAI
351 LEAPERQRTL NEIYHWFTRM FAYFRNHPAT WKNAIRHNLS LHKCFVRVES
401 EKGAVWTVDE FEFRRKKRSQR PNKCSNPCP*

Figure 2

HUMAN *FKH^f* cDNA Sequence

```

1  GCACACACTC ATCGAAAAA AATTGGATTA TTAGAAGAGA GAGGTCTGCG
51  GCTTCCACAC CGTACAGCGT GGTTTTTCTT CTCGGTATAA AAGCAAAGTT
101 GTTTTTGATA CGTGACAGTT TCCCACAAGC CAGGCTGATC CTTTTCTGTC
151 AGTCCACTTC ACCAAGCCTG CCCTTGGACA AGGACCCGAT GCCCAACCCC
201 AGGCCTGGCA AGCCCTCGGC CCCTTCCTTG GCCCTTGGCC CATCCCCAGG
251 AGCCTCGCCC AGCTGGAGGG CTGCACCCAA AGCCTCAGAC CTGCTGGGGG
301 CCCGGGGCCC AGGGGGAACC TTCCAGGGCC GAGATCTTCG AGGCGGGGCC
351 CATGCCTCCT CTTCTTCCTT GAACCCCATG CCACCATCGC AGCTGCAGCT
401 GCCCACACTG CCCCTAGTCA TGGTGGCACC CTCCGGGGCA CGGCTGGGCC
451 CCTTGCCCCA CTTACAGGCA CTCCTCCAGG ACAGGCCACA TTTCATGCAC
501 CAGCTCTCAA CGGTGGATGC CCACGCCCGG ACCCCTGTGC TGCAGGTGCA
551 CCCCCTGGAG AGCCCAGCCA TGATCAGCCT CACACCACCC ACCACCGCCA
601 CTGGGGTCTT CTCCCTCAAG GCCCGGCCTG GCCTCCCACC TGGGATCAAC
651 GTGGCCAGCC TGGAATGGGT GTCCAGGGAG CCGGCACTGC TCTGCACCTT
701 CCCAAATCCC AGTGCACCCA GGAAGGACAG CACCCTTTCG GCTGTGCCCC
751 AGAGCTCCTA CCCACTGCTG GCAAATGGTG TCTGCAAGTG GCCCGGATGT
801 GAGAAGGTCT TCGAAGAGCC AGAGGACTTC CTCAAGCACT GCCAGGCGGA
851 CCATCTTCTG GATGAGAAGG GCAGGGCACA ATGTCTCCTC CAGAGAGAGA
901 TGGTACAGTC TCTGGAGCAG CAGCTGGTGC TGGAGAAGGA GAAGCTGAGT
951 GCCATGCAGG CCCACCTGGC TGGGAAAATG GCACTGACCA AGGCTTCATC
1001 TGTGGCATCA TCCGACAAGG GCTCCTGCTG CATCGTAGCT GCTGGCAGCC
1051 AAGGCCCTGT CGTCCCAGCC TGGTCTGGCC CCCGGGAGGC CCCTGACAGC
1101 CTGTTTGCTG TCCGGAGGCA CCTGTGGGGT AGCCATGGAA ACAGCACATT
1151 CCCAGAGTTC CTCCACAACA TGGACTACTT CAAGTTCCAC AACATGCGAC
1201 CCCCTTTCAC CTACGCCACG CTCATCCGCT GGGCCATCCT GGAGGCTCCA
1251 GAGAAGCAGC GGACACTCAA TGAGATCTAC CACTGGTTCA CACGCATGTT
1301 TGCCTTCTTC AGAAACCATC CTGCCACCTG GAAGAACGCC ATCCGCCACA
1351 ACCTGAGTCT GCACAAGTGC TTTGTGCGGG TGGAGAGCGA GAAGGGGGCT
1401 GTGTGGACCG TGGATGAGCT GGAGTTCCGC AAGAAACGGA GCCAGAGGCC
1451 CAGCAGGTGT TCCAACCCTA CACCTGGCCC CTGACCTCAA GATCAAGGAA
1501 AGGAGGATGG ACGAACAGGG GCCAAACTGG TGGGAGGCAG AGGTGGTGGG
1551 GGCAGGGATG ATAGGCCCTG GATGTGCCCA CAGGGACCAA GAAGTGAGGT
1601 TTCCACTGTC TTGCCTGCCA GGGCCCTGT TCCCCGCTG GCAGCCACCC
1651 CCTCCCCCAT CATATCCTTT GCCCAAGGC TGCTCAGAGG GGCCCCGGTC
1701 CTGGCCCCAG CCCCCACCTC CGCCCCAGAC ACACCCCCCA GTCGAGCCCT
1751 GCAGCCAAAC AGAGCCTTCA CAACCAGCCA CACAGAGCCT GCCTCAGCTG
1801 CTCGCACAGA TTACTTCAGG GCTGGAAAAG TCACACAGAC ACACAAAATG
1851 TCACAATCCT GTCCCTCAC

```

Figure 3

HUMAN FKHF PROTEIN SEQUENCE

1 MPNPRPGKPS APSLALGPSP GASPSWRAAP KASDLLGARG PGGTFQGRDL
51 RGGAHASSSS LNPMPPSQLQ LPTLPLVMVA PSGARLGPLP HLQALLQDRP
101 HFMHQLSTVD AHARTPVLQV HPLESPAMIS LTPPTTATGV FSLKARPGLP
151 PGINVASLEW VSREPALLCT FPNPSAPRKD STLSAVPQSS YPLLANGVCK
201 WPGCEKVFEE PEDFLKHCQA DHLLDEKGRA QCLLOREMVO SLEQQLVLEK
251 EKLSAMQAH L AGKMALTKAS SVASSDKGSC CIVAAGSQGP VVPAWSGPRE
301 APDSLFAVRR HLWGSHGNST FPEFLHNMDY FKFHNMRPPF TYATLIRWAI
351 LEAPEKQRTL NEIYHWFTRM FAFNRNHPAT WKNAIRHNLS LHKCFVRVES
401 EKGAVWTVDE LEFRKKRSQR PSRCSNPTPG P*

Figure 4

Vector for generation of FKH^{sf} Transgenic mice



Figure 5

FKHsf Transgene corrects the defect in scurfy animals




Figure 6

**FKHsf tg mice have reduce lymph node cells
compared to normal cells**

	Mouse genotype	
	Normal	Scurfy Transgenic
Cell number		
Cells / LN	0.92	1.97 0.29
Cells / Thymus	0.76	0.54 0.76

Figure 7

FKHsf transgenic mice respond poorly to in vitro stimulation

	Mouse genotype	
	Normal	Scurfy Transgenic
Proliferation		
No stimulation	778	23488 596
Anti-CD3+ Anti-CD28	22932	225981 9106

Figure 8

<i>N-terminal</i>		<i>ZNF</i>	<i>Mid</i>	<i>Forkhead</i>	Human FKHL ^{sf}
83.4%		95.8%	82.8%	96.4%	
					Mouse Fkhl ^{sf}

Human and mouse FKHL^{sf} proteins are highly conserved.

Figure 10

Date 21 October 1999
Residence : City of Seattle, County of King
State of Washington
Citizenship : United States of America
P.O. Address : 9829 Triton Drive NW
Seattle, Washington 98117

P.O. Address : 7327 17th Avenue NW
Seattle, Washington ~~98110~~ 98117

Date Oct. 19th, 1999

Residence : Bainbridge Island, County of Kitsap
State of Washington

Citizenship : United States of America

P.O. Address : 1161 Grow Avenue NW
Bainbridge Island, Washington 98110

Date 10-21-99

Residence : Bainbridge Island, County of Kitsap
State of Washington

Citizenship : United States of America


P.O. Address : 9891 NE Day Road
Bainbridge Island, Washington 98110

1

[illegible]

David D. McMasters, Esq.
Seed and Berry LLP
6300 Columbia Tower
701 Fifth Avenue
Seattle, Washington 98104-7092

Darwin Discovery Ltd.
ASSIGNEE


Linda J. Nyari, Esq.
Vice President & General Counsel
Chiroscience R&D, Inc.
1725 220th Street Southeast, Suite 200
Bothell, Washington 98021

Winword\ddm\8802\vl

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mary E. Brunkow et al.
Application No. : 09/372,668
Filed : August 11, 1999
For : IDENTIFICATION OF THE GENE CAUSING THE MOUSE
SCURFY PHENOTYPE AND ITS HUMAN ORTHOLOG

Examiner : S. Kaushal
Art Unit : 1633
Docket No. : 240083.501
Date : June 26, 2000

Assistant Commissioner for Patents
Washington, DC 20231

APPOINTMENT OF ASSOCIATE POWER OF ATTORNEY


Assistant Commissioner for Patents:

I, Jane E. R. Potter, attorney of record in the above-identified application, appoint as associate attorney Gary M. Myles, Ph.D., Registration No. 46,209, of the firm of Seed Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 6300, Seattle, Washington 98104-7092.

It is requested that correspondence continue to be addressed to Gary M. Myles, Ph.D.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC


Jane E. R. Potter
Registration No. 33,332

JEP:cew

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

09696867-103600